CLOs on the Move

Curran Biotech

www.curranbiotech.com

 
Curran Biotech is a materials manufacturing company that provides nano coatings to biochemical, chemical, energy and construction industries including water-repellent coatings for fabrics, canvas, tarps, and glass. Our hydrophobic coatings are specifically designed to improve the nature and quality of the substrates by preventing water-substrate interactions. The technology was developed in the materials/chemistry labs (Institute for Nano Energy) of the physics department at the University of Houston and started commercialization in 2013.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.curranbiotech.com
  • 5000 Gulf Freeway Building 5, Room No 120/122
    Houston, TX USA 77023
  • Phone: 832.671.6647

Executives

Name Title Contact Details

Similar Companies

Industrial Biotechnology Corporation

Industrial Biotechnology Corporation is a Sarasota, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Metametrix

Metametrix is a Duluth, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

LogicBio

We are a genome editing company developing genetic medicines for the fight against rare pediatric diseases. GeneRide™ is a promoterless and nuclease-free approach to gene insertion which may improve the safety profile of AAV based gene therapies With GeneRide™, the therapeutic gene is site-specifically integrated into the genome allowing durable gene expression in dividing cells and mature tissues. Furthermore, therapeutic gene expression is regulated by the targeted locus so production can be limited to specific cell types.

THEON Therapeutics

THEON is a patient-focused drug discovery company developing small molecule correctors of RNA pathobiology.

BioClin Therapeutics Inc

BioClin Therapeutics, Inc. is a privately-held biotechnology developing biologics to address medical conditions where there is significant unmet need. Our lead program is a human monoclonal antibody, B-701, that targets and blocks the activity of FGFR3 (fibroblast growth factor receptor 3) and is the most advanced FGFR3-specific antagonist in development. B-701 has been tested in two Phase 1 clinical trials involving 40 patients and demonstrated potential efficacy in patients with metastatic bladder cancer who were receiving it as 2nd line therapy.